Shares of Exelixis Inc. (EXEL) were up more than 8% in extended trading on Monday, following positive updated results from a subgroup analysis of the company’s phase III pivotal trial of Cabozantinib in advanced renal cell carcinoma, dubbed METEOR.
Forex – financial instrument.Forex news
Shares of Exelixis Inc. (EXEL) were up more than 8% in extended trading on Monday, following positive updated results from a subgroup analysis of the company’s phase III pivotal trial of Cabozantinib in advanced renal cell carcinoma, dubbed METEOR.